Halkin H, Mazar A, Almog S, Schnaps Y
Eur J Clin Pharmacol. 1982;23(3):225-8. doi: 10.1007/BF00547558.
Fifteen adult chronic asthmatic patients were studied on 6 consecutive days of the second week of treatment with a new sustained release theophylline formulation, and 8 were again studied after three months on the same dosing regimen (375 mg b.i.d.). Serum theophylline concentrations were maintained in the therapeutic range (peak - 19.7 +/- 5.0 micrograms/ml; trough - 13.0 +/- 3.2 micrograms/ml) throughout the 12 hour dosing interval, and were greater than 75% of the peak concentration over 8.6 +/- 2.9 h. A degree of drug accumulation was evident in that the 1-h and 5-h levels rose from 12.2 +/- 4.1 and 4.5 +/- 4.8 micrograms/ml during the second week to 16.9 +/- 4.6 and 18.4 +/- 4.5 micrograms/ml, respectively, at three months. Between-patient differences accounted for 61%-71% of the total variation in steady state theophylline concentrations. After accounting for differences due to sampling time and assay error, unexplained random, within-individual variability amounted to 11%-18% of the total. Quantitative estimation of these components of variability may be incorporated into dosage forecasting methods based on single determinations of serum concentration.
15名成年慢性哮喘患者在接受一种新型缓释茶碱制剂治疗的第二周连续6天接受研究,其中8名患者在三个月后按照相同给药方案(375毫克,每日两次)再次接受研究。在整个12小时给药间隔期间,血清茶碱浓度维持在治疗范围内(峰值 - 19.7±5.0微克/毫升;谷值 - 13.0±3.2微克/毫升),并且在8.6±2.9小时内高于峰值浓度的75%。药物蓄积程度明显,因为在三个月时,1小时和5小时的水平分别从第二周的12.2±4.1微克/毫升和4.5±4.8微克/毫升升至16.9±4.6微克/毫升和18.4±4.5微克/毫升。患者间差异占稳态茶碱浓度总变异的61%-71%。在考虑采样时间和检测误差导致的差异后,无法解释的随机个体内变异性占总量的11%-18%。这些变异性成分的定量估计可纳入基于血清浓度单次测定的剂量预测方法中。